Clinical Studies

Strategic Partnerships to Accelerate Enrollment and Orphan Drug Development.

CENTOGENE's Clinical Studies Programs

Accelerating the Discovery and Development of Orphan Drugs for Pharmaceutical Partners

We are focused on leveraging our vast knowledge-base to support drug development for the rare disease industry in various ways including supporting clinical studies requirements. We currently have collaboration agreements with over 25 pharmaceutical partners including Denali Therapeutics, Evotec AG, Orphazyme, Aldeyra Therapeutics and Chiesi Germany.

Services in our clinical studies span the full spectrum of customized solutions for orphan drug development including in vitro molecular screening, epidemiological studies, biomarker development as well as patient recruitment and identification. We believe these services support the speed and efficiency of our pharmaceutical partners’ orphan drug development efforts and accelerate bringing new diagnostic and treatment solutions and monitoring to rare hereditary disease patients. 

Our joint projects involve thousands of patients affected with such disorders. We conduct numerous biomarker studies, iPS (induced pluripotent stem cell) studies as well as patient identification programs worldwide. Our studies yield a rich collection of genetic, biochemical and clinical data, facilitated by the use of highly innovative analytical platforms based on genomics, proteomics and metabolomics. These are used e.g. to identify and validate new biomarkers of affected patients, like lyso-Gb1 for Gaucher disease or 509 for Niemann Pick type C1/C2 disease. Furthermore, the programs help patients by providing them with early identification, monitoring and guidance on treatment options. Pharma partners are provided with a wealth of information for their orphan drug trial programs fostering the development of new therapies.


  • Centogene services in clinical studies span the full spectrum of customized solutions for orphan drug development including in vitro molecular screening, epidemiological studies, biomarker development as well as patient recruitment and identification.
  • Centogene established collaboration agreements with over 25 pharmaceutical partners including Denali Therapeutics, Evotec AG, Orphazyme, Aldeyra Therapeutics and Chiesi Germany. Our joint projects involve thousands of patients affected with rare hereditary disorders. Pharma partners are provided with a wealth of information for their orphan drug trial programs fostering the development of new therapies.
  • Centogene clinical studies yield a rich collection of genetic, biochemical and clinical data, facilitated by the use of highly innovative analytical platforms based on genomics, proteomics and metabolomics and  are a powerful tool that helps patients by providing them with early identification, monitoring and guidance on treatment options.